1491P - Assessment of psychiatric disorder in patients with metastatic breast cancer: A cross-sectional study

Background

In patients with cancer, anxiety is the most frequent comorbid psychiatric disorder, followed by depression, tobacco and alcohol abuse.

Methods

This is a cross-sectional study using the MMSE, HADS, BSI, and WHOQOL-Bref scale and aims to screen patients (pts) with metastatic breast cancer for psychiatric disorders and to assess the quality of life.

Results

A total of 91 female pts were included with a median age of 55 years; 57 pts had ECOG-PS 0; 69 pts were postmenopausal; 15 pts had a history of PD and used psychiatric medication; 24 pts were smokers and 11 had moderate alcohol habits; 55 pts were an initial stage IV. Luminal B-like Her2-negative was the most common molecular subtype (n=43); at screening 58 pts were being treated with 2^nd or later lines of treatment. HADS scale: 17 pts had anxiety and 16 pts had depression. BSI scale: 2 pts had a positive score. Anxiety was shown to be related to chemically induced menopause (p<0.001), non-metastatic disease at diagnosis (p = 0.005), and lack of therapeutic adherence in the 1^st line of palliative treatment (p = 0.009). Depression was more frequent in pts who underwent a mastectomy with lymphadenectomy (p=0.022), had luminal B tumors (p = 0.020), and experienced toxicity in the 1^st and 3^rd line of palliative treatment (p = 0.018, p = 0.031). BSI scale score was related to alcoholic habits (p = 0.013). Domain 1 of the WHOQOL-Bref had a statistically significant association with ECOG-PS, menopause, alcoholic habits, initial stage, and toxicity with the 1^st line of palliative treatment; domain 2 with ECOG-PS, menopause, the initial stage and palliative treatment of 2^nd and 3^rd line; domain 3 with ECOG-PS, menopause, palliative treatment of 1^st and 2^nd line and toxicity in 2^nd and 3^rd line; domain 4 with use of previous psychiatric medication, initial stage, molecular subtype and lack of therapeutic adherence in the 2^nd and 3^rd line (p < 0.05).

Conclusions

The prevalence of psychiatric disorders and its impact on the quality of life of patients with breast cancer is significant and it is therefore important to screen for it.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.